107 related articles for article (PubMed ID: 28982871)
1. Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab.
Sudo K; Sato K; Sakamoto S; Hasegawa Y; Asano M; Okuda Y; Takeda M; Sano M; Watanabe H; Shioya T; Ito H
Anticancer Res; 2017 Oct; 37(10):5565-5571. PubMed ID: 28982871
[TBL] [Abstract][Full Text] [Related]
2. Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients.
Muto S; Takagi H; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Shio Y; Suzuki H
Anticancer Res; 2017 Jun; 37(6):3169-3174. PubMed ID: 28551660
[TBL] [Abstract][Full Text] [Related]
3. TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer.
Takeuchi A; Oguri T; Yamashita Y; Sone K; Fukuda S; Takakuwa O; Uemura T; Maeno K; Fukumitsu K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
Anticancer Res; 2018 Sep; 38(9):5489-5495. PubMed ID: 30194207
[TBL] [Abstract][Full Text] [Related]
4. (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.
Chen B; Zhao G; Ma Q; Ji B; Ji T; Xin H; Gao S
Int J Clin Exp Pathol; 2015; 8(12):16064-72. PubMed ID: 26884883
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.
De Castro J; González-Larriba JL; Vázquez S; Massutí B; Sanchez-Torres JM; Dómine M; Garrido P; Calles A; Artal A; Collado R; García R; Sereno M; Majem M; Macías JA; Juan O; Gómez-Codina J; Hernández B; Lázaro M; Ortega AL; Cobo M; Trigo JM; Carcereny E; Rolfo C; Macia S; Muñoz J; Diz P; Méndez M; Rosillo F; Paz-Ares L; Cardona JV; Isla D
Clin Transl Oncol; 2017 Feb; 19(2):219-226. PubMed ID: 27371031
[TBL] [Abstract][Full Text] [Related]
6. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
Lynch TJ; Spigel DR; Brahmer J; Fischbach N; Garst J; Jahanzeb M; Kumar P; Vidaver RM; Wozniak AJ; Fish S; Flick ED; Leon L; Hazard SJ; Kosty MP;
J Thorac Oncol; 2014 Sep; 9(9):1332-9. PubMed ID: 25122429
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Nishino K; Imamura F; Kumagai T; Katakami N; Hata A; Okuda C; Urata Y; Hattori Y; Tachihara M; Yokota S; Nishimura T; Kaneda T; Satouchi M; Morita S; Negoro S
Lung Cancer; 2015 Aug; 89(2):146-53. PubMed ID: 26093793
[TBL] [Abstract][Full Text] [Related]
10. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
Takagi Y; Hosomi Y; Oshita F; Okamoto H; Seki N; Minato K; Aono H; Yamada K; Okuma Y; Hida N; Sakamoto T; Miura Y; Yomota M; Satoh A; Kunitoh H; Sakamaki K; Shibuya M; Watanabe K
BMC Cancer; 2015 Oct; 15():740. PubMed ID: 26481215
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
12. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
[TBL] [Abstract][Full Text] [Related]
15. Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer.
Karayama M; Inui N; Kusagaya H; Suzuki S; Inoue Y; Enomoto N; Fujisawa T; Nakamura Y; Suda T
Cancer Chemother Pharmacol; 2016 May; 77(5):1011-8. PubMed ID: 27034279
[TBL] [Abstract][Full Text] [Related]
16. Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
Le Moulec S; Hadoux J; Gontier E; Chargari C; Helissey C; Lamand V; Tanz R; Farace F; Vedrine L; Bonardel G; Soria JC; Besse B
Bull Cancer; 2013 Dec; 100(12):30-7. PubMed ID: 24316967
[TBL] [Abstract][Full Text] [Related]
17. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin-Paclitaxel: A Prospective Study.
Otsuka T; Nojiri T; Minami S; Hosoda H; Kuroyama M; Hirata H; Nakanishi K; Yamamoto S; Komuta K; Kangawa K; Kijima T
Anticancer Res; 2017 Jul; 37(7):3505-3512. PubMed ID: 28668839
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases.
Tokito T; Shukuya T; Akamatsu H; Taira T; Ono A; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Yamamoto N
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1493-8. PubMed ID: 23532208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
